FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma

0 Tampilan· 09/21/23
OncLive® On Air
OncLive® On Air
0 Pelanggan
0
Di

Dr Nooka discusses the FDA approval of elranatamab in relapsed/refractory multiple myeloma, key data from MagnetisMM-3, and the evolving role of bispecific antibodies in the multiple myeloma treatment paradigm.

Menampilkan lebih banyak

 0 Komentar sort   Sortir dengan


Berikutnya